SC
NTLA icon

Steven Cohen’s Intellia Therapeutics NTLA Stock Holding History

Steven Cohen’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.43M Buy
143,700
+116,700
+432% +$1.63M ﹤0.01% 2254
2026
Q1 		$346K Buy
27,000
+2,900
+12% +$36.9K ﹤0.01% 3307
2025
Q4 		$217K Buy
+24,100
New +$332K ﹤0.01% 3609

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Steven Cohen's NTLA Position: Q2 2026 in Review

Steven Cohen increased its Intellia Therapeutics (NTLA) stake by 48% in Q2 2026, buying an estimated $1.8M and bringing the position to 398,463 shares worth $6.74M. The position accounts for 0.01% of the portfolio, ranked #1558.

Steven Cohen first reported a position in NTLA in Q2 2020 and has held it in 7 quarters since. The position peaked at $18.3M in Q2 2020. 326 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Steven Cohen held 398,463 shares of Intellia Therapeutics worth $6.74M as of Q2 2026.
  • Steven Cohen bought 128,452 Intellia Therapeutics shares in Q2 2026, an estimated $1.8M.
  • Intellia Therapeutics made up 0.01% of Steven Cohen's portfolio in Q2 2026, its #1558 holding.
  • Steven Cohen first reported a position in Intellia Therapeutics in Q2 2020 and has held it in 7 quarters since.
  • Steven Cohen's Intellia Therapeutics position peaked at $18.3M in Q2 2020.
  • 326 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.